Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma

Cancer

Volumn 122, Issue 13, 2016, Pages 2050-2056

  Orlowski, Robert Z ^a   Nagler, Arnon ^b   Sonneveld, Pieter ^c   Bladé, Joan ^d   Hajek, Roman ^e   Spencer, Andrew ^f   Robak, Tadeusz ^g   Dmoszynska, Anna ^h   Horvath, Noemi ⁱ   Spicka, Ivan ^j   Sutherland, Heather J ^k   Suvorov, Alexander N ^l   Xiu, Liang ^m   Cakana, Andrew ^m   Parekh, Trilok ^m   San Miguel, Jesús F ⁿ  

^a UNIVERSITY OF TEXAS   (United States)

^b SHEBA MEDICAL CENTER   (Israel)

^c ERASMUS MC CANCER INSTITUTE   (Netherlands)

^d UNIVERSITY OF BARCELONA   (Spain)

^e UNIVERSITY HOSPITAL OSTRAVA   (Czech Republic)

^f ALFRED HOSPITAL   (Australia)

^g MEDICAL UNIVERSITY OF LODZ   (Poland)

^h MEDICAL UNIVERSITY OF LUBLIN   (Poland)

ⁱ ROYAL ADELAIDE HOSPITAL   (Australia)

^j CHARLES UNIVERSITY   (Czech Republic)

^k UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^l First Republican Clinical Hospital of the Ministry of Healthcare of the Udmurt Republic   (Russian Federation)

^m JANSSEN RESEARCH AND DEVELOPMENT   (United States)

ⁿ UNIVERSITY OF NAVARRA   (Spain)

more..

Author keywords

bortezomib; doxorubicin; multiple myeloma; pegylated liposomal doxorubicin; survival

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; MELPHALAN; PREDNISOLONE; PREDNISONE; THALIDOMIDE; VINCRISTINE; ANTINEOPLASTIC AGENT; MACROGOL DERIVATIVE;

AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CONTROLLED STUDY; DEATH; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE MYELOMA; OPEN STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MORTALITY; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADMINISTRATION, INTRAVENOUS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORTEZOMIB; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; POLYETHYLENE GLYCOLS; TREATMENT OUTCOME;

EID: 84971482810     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.30026     Document Type: Article

References (16)

1. Munshi NC, Anderson KC. New strategies in the treatment of multiple myeloma. Clin Cancer Res. 2013;19:3337-3344.
2. Redic K. Carfilzomib: a novel agent for multiple myeloma. J Pharm Pharmacol. 2013;65:1095-1106.
3. Barlogie B, Anaissie E, van Rhee F, et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol. 2007;138:176-185.
4. Jakubowiak AJ, Kendall T, Al-Zoubi A, et al. Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma. J Clin Oncol. 2009;27:5015-5022.2009;27:5015–5022.
5. Offidani M, Corvatta L, Piersantelli MN, et al. Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma. Blood. 2006;108:2159-2164.
6. San-Miguel JF, Schlag R, Khuageva N, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359:906–917.
7. Voorhees PM, Orlowski RZ, Mulkey F, et al. Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CLAGB (Alliance) 10303, a multicenter phase II study. Br J Haematol. 2015;171:373–377.
8. Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007;25:3892-3901.
9. Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 2003;101:2377-2380.
10. Orlowski RZ, Voorhees PM, Garcia RA, et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood. 2005;105:3058-3065.
11. Sonneveld P, Hajek R, Nagler A, et al. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. Cancer. 2008;112:1529-1537.
12. Blade J, Sonneveld P, San Miguel JF, et al. Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment. Clin Lymphoma Myeloma. 2008;8:352-355.
13. Garderet L, Iacobelli S, Moreau P, et al. Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 randomized phase III trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2012;30:2475-2482.
14. Moreau P, Richardson PG, Cavo M, et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood. 2012;120:947-959.
15. Wright JJ. Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy. Clin Cancer Res. 2010;16:4094-4104.
16. Lonial S, Mitsiades CS, Richardson PG. Treatment options for relapsed and refractory multiple myeloma. Clin Cancer Res. 2011;17:1264-1277.